# Armata Pharmaceuticals

AP-SA02, an IV phage cocktail dosed alongside standard antibiotics for complicated S. aureus bacteremia, read out positive Phase 2a data in May 2025, received FDA Qualified Infectious Disease Product designation,…


Source: https://cn.bioecon.ru/companies/armata-pharmaceuticals/
Updated: 2026-08-15

- 国家: United States
- 代码: ARMP

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 融资 | 美国国防部(DoD)为AP-SA02研发提供的总资助$2870万 | https://www.armatapharma.com/pipeline/ap-sa02/, https://www.sec.gov/Archives/edgar/data/921114/000110465926084861/tm2620782d2_ex99-1.htm |
| 产能 | 每年提供超过10,000个完整的噬菌体治疗疗程 | https://www.sec.gov/Archives/edgar/data/921114/000110465925050219/tm2515395d1_ex99-1.htm |
| 监管批准 | AP-SA02获得合格传染病产品（QIDP）及快速通道（Fast Track）资格 | https://www.armatapharma.com/pipeline/ap-sa02/, https://www.prnewswire.com/news-releases/armata-pharmaceuticals-receives-fda-qualified-infectious-disease-product-qidp-designation-for-ap-sa02-302694147.html, https://www.sec.gov/Archives/edgar/data/921114/000110465926084861/tm2620782d2_ex99-1.htm |
| 生产基地 | 位于加州洛杉矶的cGMP生产工厂 | https://www.prnewswire.com/news-releases/armata-pharmaceuticals-announces-formal-commissioning-of-state-of-the-art-cgmp-phage-manufacturing-facility-in-los-angeles-california-302607412.html, https://www.sec.gov/Archives/edgar/data/921114/000110465925050219/tm2515395d1_ex99-1.htm |
| 营收 | 截至2025年12月31日止年度资助及奖励收入$4.9 million | https://www.prnewswire.com/news-releases/armata-pharmaceuticals-announces-fourth-quarter-and-full-year-2025-financial-results-302725089.html, https://www.sec.gov/Archives/edgar/data/921114/000110465926034523/armp-20260325xex99d1.htm |

独立来源: prnewswire.com, sec.gov

## 技术

- [噬菌体疗法](https://cn.bioecon.ru/technology/bacteriophage-therapy/)